Teng Ming-Sheng, Hsu Lung-An, Wu Semon, Sun Yu-Chen, Juan Shu-Hui, Ko Yu-Lin
Graduate Institute of Medical Sciences, Department of Physiology, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan.
The First Cardiovascular Division, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
PLoS One. 2015 Apr 13;10(4):e0122664. doi: 10.1371/journal.pone.0122664. eCollection 2015.
Previous genome-wide association studies have indicated an association between CDH13 genotypes and adiponectin levels. In this study, we used mediation analysis to assess the statistical association between CDH13 locus variants and adiponectin levels, metabolic syndrome, and related metabolic phenotypes.
A sample population of 530 Taiwanese participants was enrolled. Four CDH13 gene variants in the promoter and intron 1 regions were genotyped. After adjustment for clinical covariates, the CDH13 genotypes/haplotypes exhibited an association with the adiponectin levels (lowest P = 1.95 × 10-11 for rs4783244 and lowest P = 3.78 × 10-13 for haplotype ATTT). Significant correlations were observed between the adiponectin levels and the various metabolic syndrome-related phenotypes (all P ≤ 0.005). After further adjustment for the adiponectin levels, participants with a minor allele of rs12051272 revealed a considerable association with a more favorable metabolic profile, including higher insulin sensitivity, high-density lipoprotein cholesterol levels, lower diastolic blood pressure, circulating levels of fasting plasma glucose, and triglycerides, and as a lower risk of metabolic syndrome (all P < 0.05). The mediation analysis further revealed a suppression effect of the adiponectin levels on the association between CDH13 genotypes and metabolic syndrome and its related phenotypes (Sobel test; all P < 0.001).
The genetic polymorphisms at the CDH13 locus independently affect the adiponectin levels, whereas the adiponectin levels exhibit a suppressive effect on the association between CDH13 locus variants and various metabolic phenotypes and metabolic syndrome. In addition, these results provide further evidence of the association between the CDH13 gene variants and the risks of metabolic syndrome and atherosclerotic cardiovascular disease.
既往全基因组关联研究表明,CDH13基因分型与脂联素水平之间存在关联。在本研究中,我们采用中介分析来评估CDH13基因座变异与脂联素水平、代谢综合征及相关代谢表型之间的统计学关联。
纳入530名台湾参与者作为样本群体。对启动子和内含子1区域的4个CDH13基因变异进行基因分型。在调整临床协变量后,CDH13基因分型/单倍型与脂联素水平存在关联(rs4783244的最低P值 = 1.95×10⁻¹¹,单倍型ATTT的最低P值 = 3.78×10⁻¹³)。脂联素水平与各种代谢综合征相关表型之间存在显著相关性(所有P≤0.005)。在进一步调整脂联素水平后,rs12051272次要等位基因的参与者与更有利的代谢谱存在显著关联,包括更高的胰岛素敏感性、高密度脂蛋白胆固醇水平、更低的舒张压、空腹血糖循环水平和甘油三酯,以及更低的代谢综合征风险(所有P<0.05)。中介分析进一步揭示了脂联素水平对CDH13基因分型与代谢综合征及其相关表型之间关联的抑制作用(Sobel检验;所有P<0.001)。
CDH13基因座的遗传多态性独立影响脂联素水平,而脂联素水平对CDH13基因座变异与各种代谢表型及代谢综合征之间的关联具有抑制作用。此外,这些结果为CDH13基因变异与代谢综合征和动脉粥样硬化性心血管疾病风险之间的关联提供了进一步证据。